Biophytis is pleased to announce the appointment of Philippe Rousseau as Chief Financial Officer. He replaces Evelyne Nguyen who is leaving the company to pursue other projects, after having dedicated two years to its development. A strong experience in biotech and listed companies Philippe Rousseau has nearly 25 years of experience in the biotech industry…
Biophytis announces its participation to a Virtual Workshop the development of Function promoting therapies for the elderly, organized by the National Institute on Aging based in Baltimore, USA. Dr Waly Dioh, Chief Clinical Operations Officer of Biophytis, will present the progress of its drug candidate and will meet with public and private players as well…
Biophytis received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program ANVISA (Brazilian Health Authority) approved Biophytis’ Expanded Access Program (EAP) for hospitalized patients with severe COVID-19 and mechanically ventilated in Intensive Care Unit Sarconeos (BIO101) treatment will be given to a maximum of 80…
Decoding #BIOTECH on Maddyness Read in French “Covid-19 : ces BioTech françaises engagées dans la course aux traitements” Read article in French on www.maddyness.com
Biophytis announces the drawing of the last tranche of ORNANE under the 2020 Atlas Contract for €3 million Biophytis announces the issuance of the last 120 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €3 million under its existing convertible bond agreement with Atlas, a specialized investment fund…
Biophytis to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3 Following Phase2b/SARA-INT clinically meaningful results, Biophytis is starting first regulatory activities to advance from Phase 2 to Phase 3 development A Type B/End-of-Phase 2 meeting is planned with FDA (Food and Drug Administration) on January 24th, 2022,…
Biophytis obtains a new 10M€ loan structure with Kreos Capital Biophytis announces that the Company entered into a new loan structure with Kreos Capital. Stanislas Veillet, CEO of BIOPHYTIS, stated: “This transaction allows us to fund the final steps of our COVA phase 2-3 study in COVID-19, mostly for registration under Emergency Use Authorization with…
Biophytis announces US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (BIO101) in COVID-19 Biophytis announces that patient recruitment in the United States, paused in May while waiting for results of the Interim Analysis 2, has restarted. The Data Monitoring Committee (DMC) had recommended in September from the Interim Analysis 2…
Biophytis today reports the restated financial statements as per the Company’s previous announcement on October 7, 2021 for the periods ending December 31, 2019, December 31 2020, June 30 2020 and June 30 2021, with no impact on the Company’s cash and cash equivalent as of June 30 2021. Fullscreen Mode
Biophytis hosted a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia